Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials

Clin Immunol. 2021 Oct 21:108873. doi: 10.1016/j.clim.2021.108873. Online ahead of print.ABSTRACTAdvances in Cancer immunotherapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death ligand 1 (PD-L1) are three co-inhibitory receptors that are expressed in the tumor microenvironment. Immune checkpoint inhibitors (ICI) that target these biomarkers unleash the properties of effector T cells that are licensed to kill cancer cells. Immune checkpoint blockade has dramatically changed the treatment landscape of many cancers. In this Review, we describe the current data regarding clinical trials of ICIs in six important cancers, including hepatocellular carcinoma (HCC), renal cell cancer (RCC), hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), non-small cell lung cancer (NSCLC), and head and neck cancer carcinoma (HNSCC).PMID:34688855 | DOI:10.1016/j.clim.2021.108873

Source: Clinical Immunology - October 24, 2021 Category: Allergy & Immunology Authors: Hamidreza Akhbariyoon Yasaman Azizpour Marjan Fakhrizadeh Esfahani Mehrdad Rabiee Rad Kiarash Sadeghian Esfahani Neda Khoshavi Negin Karimi Asal Shirinisaz Fatemeh Abedi Maryam Rabiee Rad Parisa Sharifi Maryam Sadat Mirbagheri Firoozabad Source Type: research